Dr. Prina-Mello scientific interests are focused on advanced translation research in NanoMedicine (in vitro/ in vivo diagnostic, imaging and therapeutics), microfluidic, biomedical devices and tissue engineering applications of nanotechnology and nanomaterials. The continuous exploration of the dynamic interaction between nano-developed-products and biologically relevant models constitute the basic ground for Dr Prina-Mello’s multidisciplinary scientific work within and outside The Trinity Translational Medicine Institute (TTMI), the AMBER (Advanced Materials and BioEngineering Research as Science Foundation Ireland funded centre), CRANN nanoscience institute and the School of Medicine.
Dr. Prina-Mello is part of the Executive Board of the European Technology Platform of Nanomedicine, as Chair of the Characterisation and Toxicology working group. At European level, he has been involved in several EC-H2020 and FP7 projects among these EU-NCL, NoCanTher, AMCARE, MULTIFUN, NAMDIATREAM and others.
Among these, he is the principal investigator behind the TCD participation to the European Nanomedicine Characterisation Laboratory infrastructure project (H2020-Infra-1). Dr Prina Mello is also Ussher Assistant Professor in Nanomedicine and Translational Nanomedicine at the TTMI.
Prof. Yuri Volkov received his MD from the 1st Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995 and he is currently Professor and Chair of Molecular and Translational Medicine and Director of Research at the School of Medicine, TCD.
His research interests include nanomedicine and biomedical applications of nanotechnologies, molecular mechanisms of immune system functioning in health and disease, cell adhesion and migration in inflammation and cancer, intracellular signalling and cytoskeletal dynamics, advanced cell and molecular imaging. Prof. Volkov coordinates a large-scale EU FP-7 funded Consortium NAMDIATREAM which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnology-enabled toolkits for early diagnostics and treatment monitoring of major types of cancer. Prof. Volkov will lead the work towards the safety and biocompatibility assessment of innovative nanomaterials within the AMBER programme.